While most MDA-MB-231 cancer cells in the brain were biglycan-negative at 4 weeks post-cancer cell injection as analyzed by immunofluorescence, we detected rare biglycan-positive GFP+ cells (Figure 2A), confirming the existence of biglycan-expressing cancer cells in vivo at the protein level. This evidence concerns the gene BGN and cancer.